Ann: Quarterly Activities Report, page-18

Oh the tears of laughter from above, the complexities of biotech and timelines.

Please do tell us why the CO took three and half years to design the next HIV trial, even though prior 2018 (not sure if you were around) the BIT-008 trial was design by the potential pharmer's as end targets were align to what they needed to see.

The BIT-008 trial would lead to Phase III FDA trial with partner, obviously this did not happen, some on here understand the timelines used by this CO to be very flexible indeed.

The elephant in the room, why the CO did not proceed with the one compound with all the safety data to proceed to CTAP Fast and Furious FDA approved is mind blowing.

Instead they played with new formulations of the compound structure, where in the back cupboard there one with 99% efficiency and is safe in humans.

The BOD have been sleep at the wheel without the SH's best interest since 2020, the greatest health crisis in my lifetime and they have been sitting on the compound for two years.

Talk about timelines, wowwee......

Of course only my opinion from the last eight years. (yes freehold with profits) before financial advice is given by others. J8 was wise to the ways of the CO patterns.

Good luck to the unblinded